Curing Mycobacterium ulcerans infection in mice with a combination of rifampin-streptomycin or rifampin-amikacin.
The curing activities of various durations of treatment with a combination of rifampin (RIF) and either streptomycin (STR) or amikacin (AMK) in murine Mycobacterium ulcerans infection were compared in two experiments. In the first experiment, treatment was begun 1 week after infection, when the inflammatory footpad lesion had not yet occurred (preventive model), and in the second experiment, treatment was begun 6 weeks after infection, when inflammatory footpad lesions were established (curative model). In the first experiment, 4 weeks of treatment with daily RIF-STR or RIF-AMK was able to postpone the occurrence of footpad lesion by 12 weeks (RIF-STR) or 17 weeks (RIF-AMK), thus demonstrating their promising bactericidal activities, but neither treatment was able to prevent the late occurrence of footpad lesions. In the second experiment, the overall cure rates, as assessed by the lack of rebound of inflammatory lesions or remultiplication of M. ulcerans, were only 62% after 2 weeks of treatment with RIF and an aminoglycoside and 85% after 4 weeks; but the cure rate reached 100% after 8 or 12 weeks of treatment. The cure rates were slightly higher with the AMK-containing combination than with the STR-containing combination, but the difference was at the limit of significance (P=0.07). These results show that in the murine model of Buruli ulcer, 8 weeks is the optimal duration of treatment with a combination of RIF and an aminoglycoside.
Lefrançois
Sébastien
S
Laboratoire de Bactériologie-Hygiène, Faculté de Médecine Pierre et Marie Curie, Université Paris 6, and CNRM et de la Résistance aux Antituberculeux, Groupe Hospitalier Pitié-Salpêtrière, Assistance Publique Hôpital de Paris, France.
Robert
Jérôme
J
Chauffour
Aurélie
A
Ji
Baohong
B
Jarlier
Vincent
V
D000583:Amikacin / Q000494:pharmacology*; D000818:Animals; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D004195:Disease Models, Animal; D004359:Drug Therapy, Combination; D005260:Female; D051379:Mice; D008807:Mice, Inbred BALB C; D009165:Mycobacterium Infections, Nontuberculous / Q000188:drug therapy*; D019911:Mycobacterium ulcerans; D012293:Rifampin / Q000494:pharmacology*; D013307:Streptomycin / Q000494:pharmacology*; D016896:Treatment Outcome
D000900:Anti-Bacterial Agents; D000583:Amikacin; D012293:Rifampin; D013307:Streptomycin